抗乳腺癌药拉帕替尼：对脑肿瘤也有效

lao2lao2

Glaxo cancer drug Tykerb shows more brain benefits

LONDON (Reuters) - GlaxoSmithKline Plc announced further clinical trial results on Sunday underlining the ability of a drug combination including its product Tykerb to fight breast cancer that has spread to the brain.

An extension to an earlier Phase II study involving 49 patients showed 20 percent of those receiving a mix of Tykerb and Roche's Xeloda experienced at least a 50 percent volume reduction in measurable brain metastases.

The finding is significant because up to a third of women with HER2-positive metastatic breast cancer may develop brain metastases, which occur when cancer spreads from its original site.

The results were presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas.

Tykerb, a once-daily pill, was approved by U.S. regulators in March and won a conditional green light from the European Medicines Agency on Friday.

It is recommended as a treatment, in combination with Xeloda, for patients with advanced or metastatic breast cancer whose tumors over-express protein HER2.
拉帕替尼被推荐与卡培他滨联合使用，用于治疗其肿瘤过度表达HER2蛋白的晚期或转移性的乳腺癌患者。